EMA Authorised: Movymia (teriparatide) — STADA Arzneimittel AG

View source ↗

Summary

The EMA authorised Movymia, a teriparatide product by STADA Arzneimittel AG, for the treatment of osteoporosis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Movymia (teriparatide)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis. MAH: STADA Arzneimittel AG. Decision date: 22/04/2026